Confalonieri Filippo, Casarini Barbara, Papapicco Annalaura, Stiro Fabio, Piscopo Raffaele, D'Andrea Luca, Petrovski Goran, Verdina Tommaso
Department of Ophthalmology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Institute of Ophthalmology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, 41122 Modena, Italy.
Biomedicines. 2025 Jan 16;13(1):211. doi: 10.3390/biomedicines13010211.
BACKGROUND/OBJECTIVES: Micropulse laser trabeculoplasty (MLT) is gaining attention as a non-invasive treatment option for primary open-angle glaucoma (POAG), offering an alternative to traditional surgeries and medications. This systematic review evaluates the effectiveness, safety, and potential of MLT in glaucoma management.
This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, following the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) recommendations.
We identified 79 articles, and after removing duplicates and screening abstracts, 56 articles were eligible for further review. A detailed full-text analysis was conducted on 26 articles, of which 15 met the predefined inclusion criteria.
MLT shows promise as a primary or adjunctive treatment for reducing intraocular pressure (IOP) in glaucoma and ocular hypertension patients. Current evidence supports its efficacy and safety; however, additional long-term studies are needed to confirm its durability and compare its effectiveness with traditional surgical and pharmacological approaches. Standardizing treatment protocols and refining patient selection criteria could enhance MLT's clinical value and support its broader adoption in glaucoma care.
背景/目的:微脉冲激光小梁成形术(MLT)作为原发性开角型青光眼(POAG)的一种非侵入性治疗选择正受到关注,为传统手术和药物治疗提供了替代方案。本系统评价评估了MLT在青光眼治疗中的有效性、安全性和潜力。
本评价遵循系统评价和Meta分析的首选报告项目(PRISMA)指南。根据2011年牛津循证医学中心(OCEBM)的建议,采用推荐分级评估、制定和评价(GRADE)方法评估证据强度。
我们识别出79篇文章,在去除重复文章并筛选摘要后,56篇文章符合进一步审查的条件。对26篇文章进行了详细的全文分析,其中15篇符合预先定义的纳入标准。
MLT有望作为青光眼和高眼压症患者降低眼压(IOP)的主要或辅助治疗方法。目前的证据支持其有效性和安全性;然而,需要更多长期研究来证实其持久性,并将其有效性与传统手术和药物治疗方法进行比较。标准化治疗方案和完善患者选择标准可以提高MLT的临床价值,并支持其在青光眼治疗中更广泛的应用。